

Imetelstat, A Potent Telomerase Inhibitor, Inhibits the Spontaneous Growth of CFU-Meg In Vitro From Essential Thrombocythemia Patients but Not From Healthy Individuals Claudio Brunold¹*, Thomas R Braschler¹*, Ning Go, MD²*, Joi Ninomoto, PharmD²*, Hooman Kashani, MS DABT²*, **VINSELSPITAL**

UNIVERSITÄT






Monic J. Stuart, MD, MPH², Elisabeth Oppliger Leibundgut, PharmD¹, Gabriela M. Baerlocher, MD¹ ¹Hematology, University Hospital and University of Bern, Bern, Switzerland, ²Oncology, Geron Corporation, Menlo Park, CA, USA

Results and Methods

Summary and Conclusions

Patient ID	0 µM [%]	0.1 µM [%] ± SD [%]	1 μΜ [%] ±SD [%]	10 μM [%] ±SD [%]	DonorID	0 µM [%] C+	0.1 µM [%] ± SD [%] C+	1 μΜ [%] ± SD [%] C+	10 µM [%] ± SD [%] C+
1*	100	138±5.7	119 ± 3.8	46 ± 1.9	1	100	93±10	96 ± 5	86±10
2*	100	106 ± 4.3	48 ± 4.3	39 ± 4.3	2	100	109 ± 58	109 ± 51	173 ± 13
3*	100	104 ± 5.7	96 ± 11.3	44 ± 5.7	3	100	111 ± 47	122 ± 20	78 ± 16
4*	100	77 ± -	37 ± -	14 ± -					
5	100	138 ± 33.7	81 ± 23.6	52 ± 6.7		100	404 - 20	400 - 25	442 - 42
6	100	117 ± 4.9	52 ± -	45 ± 45.6	n=3	100	104 ± 38	109 ± 25	112±13
7	100	33 ± 5.9	29 ± 0.0	13±2.9					
8*	100	141 ± 9.6	49 ± 13.4	14 ± -					
9*	100	80 ± 14.1	40 ± 7.1	40 ± -					
10	100	130 ± 1.6	66 ± 8.1	3 ± 0.4					
11*	100	114 ± 0	95 ± 34.4	49 ± 7.6					
n=11	100	107 ± 8.6	79 ± 11.8	33 ± 9.4					
* JAK2V617F	-positive			••					
S	nontano	ous arowth	n of CFU-Meg	a and	Cytok	ino-stim	ulated a	owth of CF	II-Moga ar

inhibition by imetelstat



- TA was measured in MNC by TRAP assay
- standard of care.

Conflicts of interest to disclose: Ning Go, Joi Ninomoto, Hooman Kashani, Monic J. Stuart: employees of Geron Corp.; Elisabeth Oppliger Leibundgut, Gabriela M. Baerlocher: service contract and research funding by Geron Corp.

UNIVERSITÄTSSPITAL BERN HOPITAL UNIVERSITAIRE DE BERNE BERN UNIVERSITY HOSPITAL

ET Patients and Healthy Individuals

CFU-Mega (%) in Patients with ET

CFU-Mega (%) in Healthy Individuals

no inhibition by imetelstat

CFU-Mega Dose-Response Curves

Method: The dose-response analysis utilized a 4 parameter loglogistic model for Log₁₀ (colony count) by dose

Methods:

Mononuclear cells (MNC) from 3 healthy individuals and from 11 ET patients (WHO 2009 criteria) were isolated from PB and suspended in IMDM or plated into collagen \pm cytokines (TPO, IL3, IL6, SCF, EPO) and treated with 0, 0.1, 1 and 10 μ M imetelstat or a mismatch control, and incubated for several hours (cell suspensions) or 10—12 days (collagen plus 5% CO_2) at 37° C. Megs were stained and the number of CFU-Meg was scored

> Our data suggest a specificity of imetelstat for malignant megakaryocytic cells

The impact of imetelstat's clinical activity is being explored in an ongoing phase 2 study in ET patients who have failed at least one prior therapy or who refuse